BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 37996408)

  • 1. Targeting protein methylation in pancreatic cancer cells results in KRAS signaling imbalance and inhibition of autophagy.
    Montenegro MF; Martí-Díaz R; Navarro A; Tolivia J; Sánchez-Del-Campo L; Cabezas-Herrera J; Rodríguez-López JN
    Cell Death Dis; 2023 Nov; 14(11):761. PubMed ID: 37996408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SHOC2 complex-driven RAF dimerization selectively contributes to ERK pathway dynamics.
    Boned Del Río I; Young LC; Sari S; Jones GG; Ringham-Terry B; Hartig N; Rejnowicz E; Lei W; Bhamra A; Surinova S; Rodriguez-Viciana P
    Proc Natl Acad Sci U S A; 2019 Jul; 116(27):13330-13339. PubMed ID: 31213532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SHOC2-MRAS-PP1 complex positively regulates RAF activity and contributes to Noonan syndrome pathogenesis.
    Young LC; Hartig N; Boned Del Río I; Sari S; Ringham-Terry B; Wainwright JR; Jones GG; McCormick F; Rodriguez-Viciana P
    Proc Natl Acad Sci U S A; 2018 Nov; 115(45):E10576-E10585. PubMed ID: 30348783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ACAGT-007a, an ERK MAPK Signaling Modulator, in Combination with AKT Signaling Inhibition Induces Apoptosis in KRAS Mutant Pancreatic Cancer T3M4 and MIA-Pa-Ca-2 Cells.
    Khandakar GI; Satoh R; Takasaki T; Fujitani K; Tanabe G; Sakai K; Nishio K; Sugiura R
    Cells; 2022 Feb; 11(4):. PubMed ID: 35203351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
    Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
    Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KRAS(G12D)- and BRAF(V600E)-induced transformation of murine pancreatic epithelial cells requires MEK/ERK-stimulated IGF1R signaling.
    Appleman VA; Ahronian LG; Cai J; Klimstra DS; Lewis BC
    Mol Cancer Res; 2012 Sep; 10(9):1228-39. PubMed ID: 22871572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53-armed oncolytic adenovirus induces autophagy and apoptosis in KRAS and BRAF-mutant colorectal cancer cells.
    Tamura S; Tazawa H; Hori N; Li Y; Yamada M; Kikuchi S; Kuroda S; Urata Y; Kagawa S; Fujiwara T
    PLoS One; 2023; 18(11):e0294491. PubMed ID: 37972012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer.
    Bryant KL; Stalnecker CA; Zeitouni D; Klomp JE; Peng S; Tikunov AP; Gunda V; Pierobon M; Waters AM; George SD; Tomar G; Papke B; Hobbs GA; Yan L; Hayes TK; Diehl JN; Goode GD; Chaika NV; Wang Y; Zhang GF; Witkiewicz AK; Knudsen ES; Petricoin EF; Singh PK; Macdonald JM; Tran NL; Lyssiotis CA; Ying H; Kimmelman AC; Cox AD; Der CJ
    Nat Med; 2019 Apr; 25(4):628-640. PubMed ID: 30833752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KRAS-related proteins in pancreatic cancer.
    Mann KM; Ying H; Juan J; Jenkins NA; Copeland NG
    Pharmacol Ther; 2016 Dec; 168():29-42. PubMed ID: 27595930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. mTORC1 upregulation via ERK-dependent gene expression change confers intrinsic resistance to MEK inhibitors in oncogenic KRas-mutant cancer cells.
    Komatsu N; Fujita Y; Matsuda M; Aoki K
    Oncogene; 2015 Nov; 34(45):5607-16. PubMed ID: 25703330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined inhibition of the PI3K/mTOR/MEK pathway induces Bim/Mcl-1-regulated apoptosis in pancreatic cancer cells.
    Burmi RS; Maginn EN; Gabra H; Stronach EA; Wasan HS
    Cancer Biol Ther; 2019; 20(1):21-30. PubMed ID: 30261145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure of the SHOC2-MRAS-PP1C complex provides insights into RAF activation and Noonan syndrome.
    Bonsor DA; Alexander P; Snead K; Hartig N; Drew M; Messing S; Finci LI; Nissley DV; McCormick F; Esposito D; Rodriguez-Viciana P; Stephen AG; Simanshu DK
    Nat Struct Mol Biol; 2022 Oct; 29(10):966-977. PubMed ID: 36175670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.
    Halilovic E; She QB; Ye Q; Pagliarini R; Sellers WR; Solit DB; Rosen N
    Cancer Res; 2010 Sep; 70(17):6804-14. PubMed ID: 20699365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MAP kinase and autophagy pathways cooperate to maintain RAS mutant cancer cell survival.
    Lee CS; Lee LC; Yuan TL; Chakka S; Fellmann C; Lowe SW; Caplen NJ; McCormick F; Luo J
    Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4508-4517. PubMed ID: 30709910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer.
    Pettazzoni P; Viale A; Shah P; Carugo A; Ying H; Wang H; Genovese G; Seth S; Minelli R; Green T; Huang-Hobbs E; Corti D; Sanchez N; Nezi L; Marchesini M; Kapoor A; Yao W; Francesco ME; Petrocchi A; Deem AK; Scott K; Colla S; Mills GB; Fleming JB; Heffernan TP; Jones P; Toniatti C; DePinho RA; Draetta GF
    Cancer Res; 2015 Mar; 75(6):1091-101. PubMed ID: 25736685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors.
    Kazi A; Xiang S; Yang H; Chen L; Kennedy P; Ayaz M; Fletcher S; Cummings C; Lawrence HR; Beato F; Kang Y; Kim MP; Delitto A; Underwood PW; Fleming JB; Trevino JG; Hamilton AD; Sebti SM
    Clin Cancer Res; 2019 Oct; 25(19):5984-5996. PubMed ID: 31227505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genome-wide DNA methylation analysis of KRAS mutant cell lines.
    Tew BY; Durand JK; Bryant KL; Hayes TK; Peng S; Tran NL; Gooden GC; Buckley DN; Der CJ; Baldwin AS; Salhia B
    Sci Rep; 2020 Jun; 10(1):10149. PubMed ID: 32576853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overcoming Adaptive Resistance to KRAS and MEK Inhibitors by Co-targeting mTORC1/2 Complexes in Pancreatic Cancer.
    Brown WS; McDonald PC; Nemirovsky O; Awrey S; Chafe SC; Schaeffer DF; Li J; Renouf DJ; Stanger BZ; Dedhar S
    Cell Rep Med; 2020 Nov; 1(8):100131. PubMed ID: 33294856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Components of the phosphatidylserine endoplasmic reticulum to plasma membrane transport mechanism as targets for KRAS inhibition in pancreatic cancer.
    Kattan WE; Liu J; Montufar-Solis D; Liang H; Brahmendra Barathi B; van der Hoeven R; Zhou Y; Hancock JF
    Proc Natl Acad Sci U S A; 2021 Dec; 118(51):. PubMed ID: 34903667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer.
    Goodwin CM; Waters AM; Klomp JE; Javaid S; Bryant KL; Stalnecker CA; Drizyte-Miller K; Papke B; Yang R; Amparo AM; Ozkan-Dagliyan I; Baldelli E; Calvert V; Pierobon M; Sorrentino JA; Beelen AP; Bublitz N; Lüthen M; Wood KC; Petricoin EF; Sers C; McRee AJ; Cox AD; Der CJ
    Cancer Res; 2023 Jan; 83(1):141-157. PubMed ID: 36346366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.